Janssen Biotech adds to its bispecific antibody pipeline for cancer via pair of collaborations. Ipsen and Accent pair up to investigate new target for acute myeloid leukemia.

The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.